Jazz Pharmaceuticals shares rose 6.9% post-earnings, reflecting investor approval of better-than-expected revenue growth and encouraging commercial momentum across key product lines.

• Total revenues reached a record $1.1 billion in Q1 2026, marking over 19% year-over-year growth.
• Xywav sales grew 18% to $408 million with about 16,600 active patients and 425 net patient additions.
• Epidiolex sales increased 15% to $250 million, driven by 16% volume growth and expanded adult patient reach.
• Early commercial uptake of Ziihera yielded $13 million in net sales, with preparations underway for a potential GEA launch following FDA priority review.
• Generated over $400 million in cash flow and non-GAAP adjusted EPS of $6.34, supporting ongoing R&D and business development investments.